Latest Insider Transactions at Inovio Pharmaceuticals, Inc. (INO)
This section provides a real-time view of insider transactions for Inovio Pharmaceuticals, Inc. (INO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INOVIO PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INOVIO PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2024
|
Michael John Sumner Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,917
+26.19%
|
-
|
|
May 15
2024
|
Peter Kies CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,562
-9.51%
|
$33,306
$13.07 P/Share
|
|
May 15
2024
|
Peter Kies CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,771
+15.05%
|
-
|
|
May 15
2024
|
Jay Shepard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,166
+23.52%
|
-
|
|
May 15
2024
|
Simon X Benito Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,166
+17.77%
|
-
|
|
May 15
2024
|
Ann Calby Miller Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,166
+21.93%
|
-
|
|
May 15
2024
|
David B. Weiner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,166
+2.56%
|
-
|
|
May 15
2024
|
Michael John Sumner Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,386
+31.04%
|
-
|
|
May 15
2024
|
Laurent Humeau Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,703
-6.54%
|
$22,139
$13.07 P/Share
|
|
May 15
2024
|
Laurent Humeau Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,771
+15.48%
|
-
|
|
May 15
2024
|
Roger D Dansey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,166
+24.3%
|
-
|
|
May 15
2024
|
Lota S. Zoth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,166
+24.83%
|
-
|
|
May 15
2024
|
Wendy L Yarno Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,166
+20.61%
|
-
|
|
May 15
2024
|
Jacqueline Elizabeth Shea Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,718
-18.66%
|
$100,334
$13.07 P/Share
|
|
May 15
2024
|
Jacqueline Elizabeth Shea Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,745
+30.02%
|
-
|
|
May 13
2024
|
Roger D Dansey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+17.91%
|
-
|
|
May 10
2024
|
Jacqueline Elizabeth Shea Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,392
-9.2%
|
$23,920
$10.65 P/Share
|
|
May 10
2024
|
Jacqueline Elizabeth Shea Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+17.45%
|
-
|
|
Feb 26
2024
|
Peter Kies CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,466
-7.37%
|
$27,728
$8.16 P/Share
|
|
Feb 26
2024
|
Peter Kies CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,875
+11.0%
|
-
|
|
Feb 26
2024
|
Laurent Humeau Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,351
-5.41%
|
$18,808
$8.16 P/Share
|
|
Feb 26
2024
|
Laurent Humeau Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,734
+11.56%
|
-
|
|
Feb 26
2024
|
Jacqueline Elizabeth Shea Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,728
-8.48%
|
$29,824
$8.16 P/Share
|
|
Feb 26
2024
|
Jacqueline Elizabeth Shea Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,731
+14.65%
|
-
|
|
Feb 26
2024
|
David B. Weiner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,916
+1.21%
|
-
|
|
Jun 30
2023
|
Michael John Sumner Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+50.0%
|
-
|
|
Jun 05
2023
|
Lota S. Zoth Director |
SELL
Open market or private sale
|
Direct |
5,700
-9.76%
|
$0
$0.56 P/Share
|
|
May 16
2023
|
David B. Weiner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+2.0%
|
-
|
|
May 16
2023
|
Wendy L Yarno Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+20.4%
|
-
|
|
May 16
2023
|
Lota S. Zoth Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+24.54%
|
-
|
|
May 16
2023
|
Ann Calby Miller Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+22.21%
|
-
|
|
May 16
2023
|
Simon X Benito Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+16.77%
|
-
|
|
May 16
2023
|
Jay Shepard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+24.51%
|
-
|
|
May 16
2023
|
Roger D Dansey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
19,000
+30.65%
|
-
|
|
May 13
2023
|
Roger D Dansey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
12,000
+33.33%
|
-
|
|
May 10
2023
|
Jacqueline Elizabeth Shea Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
28,704
-12.66%
|
$0
$0.81 P/Share
|
|
May 10
2023
|
Jacqueline Elizabeth Shea Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
66,000
+22.54%
|
-
|
|
Mar 13
2023
|
David B. Weiner Director |
SELL
Open market or private sale
|
Direct |
5,833
-0.64%
|
$5,833
$1.15 P/Share
|
|
Mar 11
2023
|
David B. Weiner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
11,666
+1.26%
|
-
|
|
Mar 11
2023
|
Peter Kies CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
31,410
-11.7%
|
$31,410
$1.13 P/Share
|
|
Mar 11
2023
|
Peter Kies CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
59,737
+18.2%
|
-
|
|
Mar 11
2023
|
Jacqueline Elizabeth Shea Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
25,980
-13.91%
|
$25,980
$1.13 P/Share
|
|
Mar 11
2023
|
Jacqueline Elizabeth Shea Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
59,737
+24.23%
|
-
|
|
Mar 11
2023
|
Laurent Humeau Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,658
-8.78%
|
$20,658
$1.13 P/Share
|
|
Mar 11
2023
|
Laurent Humeau Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
59,737
+20.25%
|
-
|
|
Feb 27
2023
|
David B. Weiner Director |
SELL
Open market or private sale
|
Direct |
11,668
-1.27%
|
$11,668
$1.28 P/Share
|
|
Feb 26
2023
|
Laurent Humeau Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27,937
-7.74%
|
$27,937
$1.28 P/Share
|
|
Feb 26
2023
|
Laurent Humeau Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
68,811
+15.88%
|
-
|
|
Feb 26
2023
|
Peter Kies CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
41,123
-9.15%
|
$41,123
$1.28 P/Share
|
|
Feb 26
2023
|
Peter Kies CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
70,511
+13.44%
|
-
|